iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
Patient samples arrive in Tennessee from UCLA Medical Center, officially kicking off 5,000-participant, multi-center
Patient samples arrive in Tennessee from UCLA Medical Center, officially kicking off 5,000-participant, multi-center
NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,”
Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional
NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,”
NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today
Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients
